Inclusion Criteria:  Written informed consent must be obtained before any assessment is performed. U.S. adults with primary hypercholesterolemia, 40-75 years of age. Not currently taking statins or one of the dietary supplements included in the trial. Patients willing to discontinue a prohibited supplement for 4 weeks prior to enrollment will be allowed to participate. LDL-cholesterol between 70 and 189 mg/dL. Patients without diabetes mellitus and a 10-year risk of ASCVD between 5 and <20% using the pooled cohort risk equation. * Or Patients with diabetes mellitus in females 50-60 years of age or males 40-50 years of age with an LDL-C between 70-189 mg/dL and with an ASCVD risk below 20%.  Exclusion Criteria:  Age < 40 or >75 years of age Women who are pregnant, plan to become pregnant within the next 6 months, or are breastfeeding. Documented liver dysfunction or history of elevated LFTs indicating active liver disease Documented chronic renal dysfunction within the past two years defined as an eGFR<30mL/min/m2. Known hypersensitivity to rosuvastatin or any supplement under investigation (i.e. shellfish allergy, etc.). Currently taking any prescription statin, or other prescription medication/supplements to treat elevated cholesterol or triglycerides. Currently taking a medication/supplement that has known interaction with rosuvastatin, including fenofibrate, gemfibrozil, HIV medications, colchicine, cyclosporine, warfarin, anti-viral medications to treat Hepatitis C, regorafenib, and darolutamide. Are unwilling to discontinue prohibited dietary supplement(s) for 4 weeks prior to participation or during the course of the trial. Other non-prohibited supplements will be permitted if doses have been stable for at least 4 weeks. Known cardiovascular disease including a history of prior MI, stroke/TIA, PAD or prior revascularization procedures of the heart or vasculature (e.g. CABG, stenting, PCI etc.). Fasting Triglycerides >200mg/dl. In the opinion of the investigator, any other condition that will preclude participation in the study.